DISC O V ERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 DEVELOPMENT STAGE & ANTICIPATED MILESTONES COMMERCIAL RIGHTS PROGRAM THERAPEUTIC INDICATION Checkpoint Agonist T S R -042: Anti-PD-1 T S R -022: Anti - TIM-3 T S R -033: Anti-LAG-3 TSR-075: Anti-PD-1/LAG-3 Bispecific C C -90006: Anti-PD-1 Agonist Undisclosed ANB020: Anti - I L -33 ANB019: Anti - I L -36R Generalized Pustular Psoriasis Palmoplantar Pustulosis Inflammation Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Psoriasis Inflammation Phase 2a Data Presented at AAD and EAACI 2018 Phase 2b Initiated Initiated Phase 2a Top-Line Data Announced March 2018 Phase 2a Top-Line Data Anticipated Q3 2018 Phase 2 Initiated Registration Program Initiated TSR-042 Combination Ongoing Dose Escalation Completed IND Filing H2 2019 IND-Enabling Studies Q1 2018 Ongoing Ongoing Ongoing Moderate-to-Severe Baseline Adult Peanut Allergy Top-Line Data Announced November 2017 Phase 2b To Be Phase 2 To Be Initiated Presented at EAACI 2018 Phase 1 Data Moderate-to-Severe Adult Atopic Dermatitis Moderate-to-Severe Baseline Adult Peanut Allergy Severe Adult Eosinophilic Asthma